Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -0.66%6 EV-to-OCF is -17.34 as of Sep. 16, 2026. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,406 Biotechnology companies, Veraxa Biotech Holding AG ranks better than 80.3% on this metric.
The historical rank and industry rank for Veraxa Biotech Holding AG's EV-to-OCF or its related term are showing as below:
VRXA'
s EV-to-OCF Range Over the Past 10 Years
Min: -542.55 Med: 0 Max: -17.22
Current: -515.16
During the past 3 years, the highest EV-to-OCF of Veraxa Biotech Holding AG was -17.22. The lowest was -542.55. And the median was .
VRXA's EV-to-OCF is ranked better than 80.3% of 1406
companies
in the Biotechnology industry
Industry Median: -3.31
vs VRXA: -515.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veraxa Biotech Holding AG (NAS:VRXA) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veraxa Biotech Holding AG's PE Ratio (TTM) for today is calculated as:
Veraxa Biotech Holding AG's share price for today is $1.51.
Veraxa Biotech Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.214.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Veraxa Biotech Holding AG EV-to-OCF Related Terms
Veraxa Biotech Holding AG EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG EV-to-OCF Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-OCF
0.00
-450.18
-693.68
Veraxa Biotech Holding AG Quarterly Data
Jun24
Dec24
Jun25
Dec25
EV-to-OCF
0.00
-450.18
-100.63
-136.53
VRXA vs KRRO, CNXU, NKTX: EV-to-OCF Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's EV-to-OCF falls into.
Veraxa Biotech Holding AG's current Enterprise Value is $212.76 Mil.
Veraxa Biotech Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a EV-to-OCF of -17.34 as of Sep. 16, 2026. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #277 out of 1406 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Veraxa Biotech Holding AG's EV-to-OCF too high?
Veraxa Biotech Holding AG's current EV-to-OCF is -17.34. Based on the distribution chart, Veraxa Biotech Holding AG ranks #277 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's EV-to-OCF compare to KRRO and CNXU?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #277 out of 1406 companies for EV-to-OCF. This places Veraxa Biotech Holding AG in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Veraxa Biotech Holding AG's current EV-to-OCF is -17.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current EV-to-OCF of -17.34. The current EV-to-OCF is -17.34. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current EV-to-OCF is -17.34 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
